Identification of the N-acylsphingosine amidohydrolase 1 gene (ASAH1) for susceptibility to schizophrenia in a Han Chinese population

World Journal of Biological Psychiatry

Volumn 13, Issue 2, 2012, Pages 106-113

  Zhang, Huaihui ^a,b   Li, Dawei ^b   Su, Yousong ^a   Jiang, Sanduo ^a   Xu, Yifeng ^a   Jiang, Kaida ^a   Cui, Donghong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ASAH1; Association; Chinese; Schizophrenia; Susceptibility

Indexed keywords

COMPLEMENTARY DNA; ENZYME; N ACYLSPHINGOSINE AMIDOHYDROLASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ACID CERAMIDASE; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA;

EID: 84863043606     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.559273     Document Type: Article

References (54)

1. Badner JA, Gershon ES. 2002. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 7: 405-411. (Pubitemid 34499362)
2. Bar J, Linke T, Ferlinz K, Neumann U, Schuchman EH, Sandhoff K. 2001. Molecular analysis of acid ceramidase deficiency in patients with Farber disease. Hum Mutat 17:199-209. (Pubitemid 32187051)
3. Barak Y, Achiron A, Mandel M, Mirecki I, Aizenberg D. 2005. Reduced cancer incidence among patients with schizophrenia. Cancer 104:2817-2821. (Pubitemid 41798293)
4. Barrett JC. 2009. Haploview: Visualization and analysis of SNP genotype data. Cold Spring Harb Protoc 2009:pdb ip71.
5. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265. (Pubitemid 40202029)
6. Buccoliero R, Futerman AH. 2003. The roles of ceramide and complex sphingolipids in neuronal cell function. Pharmacol Res 47:409-419. (Pubitemid 36379203)
7. Buccoliero R, Bodennec J, Futerman AH. 2002. The role of sphin-golipids in neuronal development: lessons from models of sphin-golipid storage diseases. Neurochem Res 27:565-574.
8. Catts VS, Catts SV. 2000. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene? Schizophr Res 41:405-415. (Pubitemid 30109597)
9. Catts VS, Catts SV, O'Toole BI, Frost AD. 2008. Cancer incidence in patients with schizophrenia and their first-degree relatives-a meta-analysis. Acta Psychiatr Scand 117:323-336. (Pubitemid 351502440)
10. Cui DH, Jiang KD, Jiang SD, Xu YF, Yao H. 2005. The tumor suppressor adenomatous polyposis coli gene is associated with susceptibility to schizophrenia. Mol Psychiatry 10:669-677. (Pubitemid 40961737)
11. De La Vega FM. 2007. Selecting single-nucleotide polymorphisms for association studies with SNPbrowser software. Methods Mol Biol 376:177-193. (Pubitemid 350189868)
12. De La Vega FM, Isaac HI, Scafe CR. 2006. A tool for selecting SNPs for association studies based on observed linkage disequilibrium patterns. Pac Symp Biocomput: 487-498.
13. Devi AR, Gopikrishna M, Ratheesh R, Savithri G, Swarnalata G, Bashyam M. 2006. Farber lipogranulomatosis: clinical and molecular genetic analysis reveals a novel mutation in an Indian family. J Hum Genet 51:811-814. (Pubitemid 44386826)
14. Ehlert K, Frosch M, Fehse N, Zander A, Roth J, Vormoor J. 2007. Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatr Rheumatol Online J 5:15.
15. Elojeimy S, Liu X, McKillop JC, El-Zawahry AM, Holman DH, Cheng JY, et al. 2007. Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther 15:1259-1263. (Pubitemid 46965321)
16. Grinshpoon A, Barchana M, Ponizovsky A, Lipshitz I, Nahon D, Tal O, et al. 2005. Cancer in schizophrenia: is the risk higher or lower? Schizophr Res 73:333-341. (Pubitemid 40093897)
17. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. 1991. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66: 589-600.
18. Holman DH, Turner LS, El-Zawahry A, Elojeimy S, Liu X, Bielawski J, et al. 2008. Lysosomotropic acid ceramidase inhibior induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 61:231-242. (Pubitemid 350160321)
19. Innis MA, Gelfand DH, Sninsky JJ, White TJ. 1990. PCR Protocols: A guide to methods and applications. San Diedo, CA: Academic Press. p. 146-152.
20. Jablensky A, Lawrence D. 2001. Schizophrenia and cancer: is there a need to invoke a protective gene? Arch Gen Psychiatry 58:579-580. (Pubitemid 32523738)
21. Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. 2005. Apop-totic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29:846-858.
22. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276. (Pubitemid 18039085)
23. Kim HL, Satta Y. 2008. Population genetic analysis of the N-acylsphingosine amidohydrolase gene associated with mental activity in humans. Genetics 178:1505-1515.
24. Levav I, Lipshitz I, Novikov I, Pugachova I, Kohn R, Barchana M, et al. 2007. Cancer risk among parents and siblings of patients with schizophrenia. Br J Psychiatry 190:156-161.
25. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, et al. 2003. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 73:34-48. (Pubitemid 36793778)
26. Li CM, Park JH, Simonaro CM, He X, Gordon RE, Friedman AH, et al. 2002. Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. Genomics 79:218-224.
27. Lichtermann D, Karbe E, Maier W. 2000. The genetic epidemiology of schizophrenia and of schizophrenia spectrum disorders. Eur Arch Psychiatry Clin Neurosci 250:304-310. (Pubitemid 32002384)
28. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist J. 2001. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry 58:573-578. (Pubitemid 32523737)
29. Liu X, Cheng JC, Turner LS, Elojeimy S, Beckham TH, Bielawska A, et al. 2009. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets 13:1449-1458.
30. Liu X, Elojeimy S, Turner LS, Mahdy AE, Zeidan YH, Bielawska A, et al. 2008. Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci 13:2293-2298. (Pubitemid 351589254)
31. Maeda I, Takano T, Matsuzuka F, Maruyama T, Higashiyama T, Liu G, et al. 1999. Rapid screening of specific changes in mRNA in thyroid carcinomas by sequence specific-differential display: decreased expression of acid ceramidase mRNA in malignant and benign thyroid tumors. Int J Cancer 81:700-704. (Pubitemid 29214376)
32. Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, et al. 2009. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther 17:430-438.
33. Merrill AH Jr, Wang E. 1992. Enzymes of ceramide biosynthesis. Methods Enzymol 209:427-437.
34. Muramatsu T, Sakai N, Yanagihara I, Yamada M, Nishigaki T, Kokubu C, et al. 2002. Mutation analysis of the acid cerami-dase gene in Japanese patients with Farber disease. J Inherit Metab Dis 25:585-592. (Pubitemid 36266994)
35. Narayan S, Head SR, Gilmartin TJ, Dean B, Thomas EA. 2009. Evidence for disruption of sphingolipid metabolism in schizophrenia. J Neurosci Res 87:278-288.
36. Numata S, Ueno S, Iga J, Yamauchi K, Hongwei S, Hashimoto R, et al. 2008. TGFBR2 gene expression and genetic association with schizophrenia. J Psychiatr Res 42:425-432. (Pubitemid 351249856)
37. Park JH, Schuchman EH. 2006. Acid ceramidase and human disease. Biochim Biophys Acta 1758:2133-2138. (Pubitemid 44879370)
38. Park JK, Lee HJ, Kim JW, Park YH, Lee SS, Chang HI, et al. 2004. Differences in p53 gene polymorphisms between Korean schizophrenia and lung cancer patients. Schizophr Res 67:71-74. (Pubitemid 38117093)
39. Perry DK, Hannun YA. 1998. The role of ceramide in cell signaling. Biochim Biophys Acta 1436:233-243.
40. Pulver AE, Lasseter VK, Kasch L, Wolyniec P, Nestadt G, Blouin JL, et al. 1995. Schizophrenia: a genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes. Am J Med Genet 60:252-260.
41. Relative quantitation of gene expression. User Bulletin #2: ABI Prism 7700 Sequence Detection System. PE Applied Biosys-tems, 1997 (updated 10/2001).
42. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, et al. 2008. Microarray analysis of altered sphin-golipid metabolism reveals prognostic significance of sphingo-sine kinase 1 in breast cancer. Breast Cancer Res Treat 112: 41-52.
43. Ruckhaberle E, Holtrich U, Engels K, Hanker L, Gatje R, Metzler D, et al. 2009. Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer. Climacteric 12:502-513.
44. Ruvolo PP. 2003. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 47:383-392. (Pubitemid 36379200)
45. Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AE, et al. 2007. The functional effects of acid ceramidase overex-pression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 6:1455-1460. (Pubitemid 351590358)
46. Savtchouk IA, Mattie FJ, Ollis AA. 2007. Ceramide: from embryos to tumors. Sci STKE 2007:jc1.
47. Schwarz A, Futerman AH. 1997. Distinct roles for ceramide and glucosylceramide at different stages of neuronal growth. J Neurosci 17:2929-2938. (Pubitemid 27175807)
48. Seelan RS, Qian C, Yokomizo A, Bostwick DG, Smith DI, Liu W. 2000. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer 29:137-146.
49. Spiegel S, Cuvillier O, Edsall L, Kohama T, Menzeleev R, Olivera A, et al. 1998. Roles of sphingosine-1-phosphate in cell growth, differentiation, and death. Biochemistry (Moscow) 63: 69-73. (Pubitemid 128588478)
50. Tabares-Seisdedos R, Rubenstein JL. 2009. Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. Mol Psychiatry 14:563-589.
51. Usadel H, Brabender J, Danenberg KD, Jeronimo C, Harden S, Engles J, et al. 2002. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 62: 371-375. (Pubitemid 34106406)
52. Zeidan YH, Jenkins RW, Korman JB, Liu X, Obeid LM, Norris JS, et al. 2008. Molecular targeting of acid ceramidase: implications to cancer therapy. Curr Drug Targets 9:653-661.
53. Zhang HH, Cui DH, Zhu ZQ, Jiang KD, Jiang SD. 2008. Association analysis between ASAH1 gene and symptom quantitative trait of schizophrenia in Chinese Han Population. Chin J Psychiatry 41:5-9.
54. Zhang Z, Mandal AK, Mital A, Popescu N, Zimonjic D, Moser A, et al. 2000. Human acid ceramidase gene: novel mutations in Farber disease. Mol Genet Metab 70:301-309.